reports
PHARMANUTRA sees a downgrade to Neutral on account of less fundamental...
The independent financial analyst theScreener just lowered the general evaluation of PHARMANUTRA (IT), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date January 14, 2022, the closing price was EUR 71.60 and its target pri...
4 directors bought/sold
Four Directors at Pharmanutra S.P.A. bought/sold 1,091,445 shares at 14.000EUR. The significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.